X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GSK Pharma: A Sterling Performance - Outside View
 
 
GSK Pharma: A Sterling Performance

GlaxoSmithKline Pharmaceuticals--in its original avatar--may well rank as one of the oldest MNC pharma companies to set foot in India and today, still continue to be in the business of bringing succor to the sick and the ill. For the matter of record, its beginnings in India date back to 1924 when it began life as a corporate entity, with an initial paid up equity of Rs 18 m. A humungous sum of money for its time.

Cut to the new century and much water has flowed under the bridge in the last decade or so. A few mergers and a few disinvestments seem to have propelled the company into a new orbit-especially on the bottomline front.

The merger, in the main, with SmithKline Beecham Pharma in 2001 and with Burroughs Welcome in 2004 along with a few divestitures-the chemical healthcare business in 2006 and the fine chemicals business in 2007-the latter 2 bringing in a hoard of lucre. Shareholders were amply rewarded following these 2 exits. The 2 mergers led to an increase in the capital base from Rs 600 m to Rs 870 m.

In hindsight, these deft moves also saw the arrival of lady luck in abundance. Following the 2001 acquisition, sales grew almost 18% that year with the pre-tax margin on sales growing to 10.5% from 9% previously. The 2004 merger saw sales accelerating 24% but the pretax margin surged to 28%. The 2 divestitures saw margins accelerating to 33% and 35% in 2006 and 2007---with the pretax margin peaking at 40% in 2009.

Some help did come from its bulging cash reserves, accumulated partly from the sales of 2 businesses which helped free the company from all working capital costs and brought in Rs 1 bn in other income (including a dividend from its wholly owned subsidiary). This other income amounted to almost 15% of pretax income in 2009. The cash kitty including encashable securities stood at over Rs 18 bn in end 2009. Its piggly wiggly wholly owned subsidiary Biddle Sawyer is another cash cow giving the company a return of almost 38% on its equity investment through dividends.

Cumulatively, sales rose 105% over the decade to Rs 19 bn but pretax profit margins rocketed 793% to Rs 7.6 bn. Not a liitle help came from the containment of the wage bills what with the management orchestrating some neat tricks on the HR front. Employee strength which peaked at 5338 nos in 2001 reached a nadir of 3620 nos in 2007 but rose to a liitle over 4000 in 2009. It is currently on a recruitment binge, adding to its sales staff to promote its product line.

The cash hoard also led the company in 2005 to execute a neat exercise of sorts to shore up the 'reserves' of the parent. It bought back 2.6 m shares and then very thoughtfully proceeded to extinguish the shares. In this process, the parent was quietly able to raise its stake in the Indian company to subsidiary status with an increased holding of 50.7%. Why in the first place should the parent spend its own money for such a delicate exercise please?

All this brings us to the more pertinent question. What exactly is its India game plan? They are more than a mouthful going by the directors'report. The report says that the company is in the forefront of making a significant impact on the healthcare needs of the country. With this in mind it has successfully introduced a number of products in such areas as diarrhea vaccine, refractory breast cancer, cervical cancer and an antithrombotic agent. It claims it is currently developing capabilities in the new focus area of cardiovascular capabilities.

It also waxes eloquent on the strides made by its 2 R&D centres in Nashik and Thane, on which it spent Rs 80 m in 2009 and it has also re-engineered its Nashik factory which has boosted productivity to boot. Its other focus area is in clinical operations. This business brought in about Rs 80 m to the bottomline in 2009. It has also filed for a number of new drug applications with the Ministry of Health and has received approval for several.

But the fact of the matter is also that there is very little investment in fixed asset addition and besides, the bulk of its manufacturing facilities (74%) are depreciated. One was under the impression that pharma manufacture was some sort of a high tech exercise-but apparently not so, at least not anymore. It manufacturing capacities are being flogged to the brim, especially in its largest item of sales-tablets and capsules - and almost 17% of its overall sales is bought out.

Its generation of cash from operations in 2009 was a cool Rs 5 bn but only a pitiful Rs 300 m went into fixed assets in 2009. There is no clue of what the directors plan to do with all this surplus cash. Or when its new lines of business will see the day of light or, whether they plan to expand capacities of their existing products or, go in for bought out sales, or what it will cost in capital expenditure terms to create the new product lines.

But given its performance to date and given the stated intentions of the management for the future, the company seems to be an excellent longer term bet. Reserves and surplus in excess of Rs 1.6 bn against a paid up capital base of Rs 840 m is another attraction.

Disclosure: Please note that I am not a shareholder of this company

This column "Cool Hand Luke" is written by Luke Verghese. Luke has been a business journalist, financial analyst and knowledge management head with a professional experience of more than 20 years. An avid watcher of the stock market, he has written extensively on stock market trends. His articles have featured in Business Standard, Financial Express and Fortune India amongst others. He has also been the Deputy Editor, Fortune India and the Financial Editor of The Business and Political Observer.

Disclaimer:
The views mentioned above are of the author only. Data and charts, if used, in the article have been sourced from available information and have not been authenticated by any statutory authority. The author and Equitymaster do not claim it to be accurate nor accept any responsibility for the same. The views constitute only the opinions and do not constitute any guidelines or recommendation on any course of action to be followed by the reader. Please read the detailed Terms of Use of the web site.
Equitymaster Agora Research Private Limited

 

Equitymaster requests your view! Post a comment on "GSK Pharma: A Sterling Performance". Click here!

  
 

More Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More
 

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 22, 2017 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - VENUS REMEDIES COMPARISON

Compare Company With Charts

COMPARE GSK PHARMA WITH

MARKET STATS